Studies how often BAP1 gene changes run in families and their effects
Observes people with inherited BAP1 gene changes to learn about related cancers.
Key facts
- Who runs it
- Mohamed Abdel-Rahman
- Where
- Columbus, United StatesSee the site
- Trial code
- Registry title
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 3 Mar 2015
- Expected to end
- 1 Jul 2027
- Type of study
- Observational, 2 groups
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with certain cancers or a family history of cancers linked to BAP1 hereditary cancer syndrome, people with a BAP1 gene change, and their at-risk relatives.
- Sex
- All sexes can join.
- Disease stage
- Cancers linked to BAP1 syndrome, such as uveal melanoma, cutaneous melanoma, mesothelioma, renal cell carcinoma, cholangiocarcinoma, meningioma and hepatocellular carcinoma. People without cancer can also join if they have a documented BAP1 variant or are an at-risk relative.
- Biomarker or test result
- A documented BAP1 pathogenic or likely pathogenic variant, or a BAP1 variant of uncertain significance together with a BAP1-related cancer.
Main reasons for not taking part
- People who do not speak English cannot join, because the study material and consent forms are only in English.
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients who meet any of the following criteria:
- Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, meningioma and hepatocellular carcinoma
- Any patient with personal history of at least 2 cancers reported in hereditary BAP1 cancer predisposition syndrome
- Any subject (affected or unaffected) with a documented BAP1 pathogenic/ likely pathogenic variant
- Any patient with a cancer reported in BAP1 and a germline variant of uncertain significance
- At risk relatives of a patient with documented BAP1 mutation
Who cannot take part
- Study material including consent forms are currently only available in English so non-English speaking subjects are excluding
Where in United States
- The Ohio State University -Wexner Medical CenterColumbus, United StatesContact: Mohamed H Abdel-Rahman, MD, PhDTaking people
About the trial
What the trial wants to find out
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screening and earlier intervention which would improve the treatment outcome not only for retaining vision but also for overall survival. Similarly in patients with germline BAP1 mutation CM develops in premalignant atypical melanocytic lesions and careful follow up of these patients will improve the outcome of their disease. In addition this study could have impact on the management of patients with personal and/or family history of several other cancers reported in patients with germline BAP1 mutation such as mesothelioma, renal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, meningioma and basal cell carcinoma.
The 2 groups in the trial
- Patients with personal and/or family history suggestive of hereditary BAP1
Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, hepatocellular carcinoma and meningioma
- Pathogenic, likely pathogenic variants in BAP1 and variants of uncertain significance
Affected and unaffected individuals with pathogenic or likely pathogenic variant in BAP1 and their family members Patients with personal family history of any of the BAP1 associated cancer and a variant of uncertain significance of BAP1
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- Plain-language title
- Studies how often BAP1 gene changes run in families and their effectsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 October 2026